Clinical review
introduction of antipsychotics into primary health care
DOI:
https://doi.org/10.5712/rbmfc18(45)2930Keywords:
Psychotic Disorders, Primary health care, Antipsychotic agents.Abstract
Antipsychotics are the first line of treatment for psychotic symptoms and syndromes. Psychosis can present itself as: delusions, hallucinations, disorganized thinking, and altered behavior. It is estimated that 13 to 23% of the population will experience these symptoms at some point in their lifetime. This clinical review aims to assist in the decision-making about when and how to introduce antipsychotics into primary health care, considering their effectiveness, side effect profile, and the main care practices for relevant comorbidities. A literature review was carried out in the electronic databases PubMed, BMJ Best Practice, and UpToDate — electronic databases summarizing evidence — from October to November 2020. Articles that addressed the introduction of antipsychotics into primary health care, in patients over 18 years of age, published after 2010, in Portuguese, English, Spanish or French, were included. A total of 76 articles were considered eligible. Of these, 27 were selected for full reading. The antipsychotic should be recommended for anyone who experiences a first episode of psychosis. Preferably, the therapeutic choice should be part of a person-centered shared decision-making, considering the side effects. There is no superiority in effectiveness between one antipsychotic or another, not even between groups. The profile of efficacy, adverse effects, safety, and tolerability of the main drugs available were analyzed, facilitating decision-making regarding the introduction of antipsychotics. Due to the scarce national literature, it was not possible to analyze the specific profile for the Brazilian population.
Downloads
Metrics
References
BMJ Publishing Group Limited. BMJ Best Practice [Internet]. [acessado em 17 dec. 2020]. Disponível em: https://bestpractice.bmj.com/info/pt/
UpToDate Marketing Professional. UpToDate [Internet]. [acessado em 17 dec. 2020]. Disponível em: https://www.uptodate.com/contents/search DOI: https://doi.org/10.1097/01.NPR.0000794532.62172.af
Cooper SJ, Reynolds GP, Barnes TRE, England E, Haddad PM, Heald A, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016;30(8):717-48. https://doi.org/10.1177/0269881116645254 DOI: https://doi.org/10.1177/0269881116645254
Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract 2014;20(3):196-206. https://doi.org/10.1097/01.pra.0000450319.21859.6d DOI: https://doi.org/10.1097/01.pra.0000450319.21859.6d
Bighelli I, Ostuzzi G, Girlanda F, Cipriani A, Becker T, Koesters M, et al. Implementation of treatment guidelines for specialist mental health care. Cochrane Database Syst Rev 2016;12(12):CD009780. https://doi.org/10.1002/14651858.CD009780.pub3 DOI: https://doi.org/10.1002/14651858.CD009780.pub3
Psychosis and schizophrenia in adults: prevention and management. London: National Institute for Health and Care Excellence (NICE); 2014. PMID: 32207892
Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25(5):567-620. https://doi.org/10.1177/0269881110391123 DOI: https://doi.org/10.1177/0269881110391123
BRASIL. Cadernos de Atenção Básica [Internet]. Brasília: Ministério da Saúde; 2013. [acessado em 17 dec. 2020]. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/cadernos_atencao_basica_34_saude_mental.pdf
Barbui C, Girlanda F, Ay E, Cipriani A, Becker T, Koesters M. Implementation of treatment guidelines for specialist mental health care. Cochrane Database Syst Rev 2014;(1):CD009780. https://doi.org/10.1002/14651858.CD009780.pub2 DOI: https://doi.org/10.1002/14651858.CD009780.pub2
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69(3):548-56. PMID: 14971837
Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry 2017;62(9):604-16. https://doi.org/10.1177/0706743717720448 DOI: https://doi.org/10.1177/0706743717720448
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62. https://doi.org/10.1016/S0140-6736(13)60733-3 DOI: https://doi.org/10.1016/S0140-6736(13)60733-3
World Health Organization. Pharmacological treatment of mental disorders in primary health care. Geneva: WHO; 2009. PMID: 23762966
Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011;25(6):473-90. https://doi.org/10.2165/11587800-000000000-00000 DOI: https://doi.org/10.2165/11587800-000000000-00000
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410-72. https://doi.org/10.1177/0004867416641195 DOI: https://doi.org/10.1177/0004867416641195
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71-93. https://doi.org/10.1093/schbul/sbp116 DOI: https://doi.org/10.1093/schbul/sbp116
De Berardis D, Serroni N, Campanella D, Olivieri L, Ferri F, Carano A, et al. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 2012;7(1):55-62. https://doi.org/10.2174/157488612800492681 DOI: https://doi.org/10.2174/157488612800492681
Brasil. Relação Nacional de Medicamentos Essenciais 2020: Rename 2020 [Internet]. Brasília: Ministério da Saúde; 2020. [acessado em 7 feb. 2022]. Disponível em: http://portalms.saude.gov.br/assistencia-farmaceutica/medicamentos-rename
Puyat JH, Daw JR, Cunningham CM, Law MR, Wong ST, Greyson DL, et al. Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 2013;48(12):1861-72. https://doi.org/10.1007/s00127-013-0753-4 DOI: https://doi.org/10.1007/s00127-013-0753-4
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8(2):114-26. https://doi.org/10.1038/nrendo.2011.156 DOI: https://doi.org/10.1038/nrendo.2011.156
Froes Brandao D, Strasser-Weippl K, Goss PE. Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review. Cancer 2016;122(2):184-8. https://doi.org/10.1002/cncr.29714 DOI: https://doi.org/10.1002/cncr.29714
Organização Panamericana da Saúde. Rede Pan-Americana de Harmonização da Regulamentação Farmaêutica Documento Técnico No 5. Washington: OPAS; 2011. 1-85 p.
Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011;26(3):130-40. https://doi.org/10.1097/YIC.0b013e328341e434 DOI: https://doi.org/10.1097/YIC.0b013e328341e434
La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 2013;46(6):201-8. https://doi.org/10.1055/s-0033-1347177 DOI: https://doi.org/10.1055/s-0033-1347177
Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167(6):686-93. https://doi.org/10.1176/appi.ajp.2009.09060802 DOI: https://doi.org/10.1176/appi.ajp.2009.09060802
Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas SHL, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. Clin Pharmacol Ther 2016;99(3):306-14. https://doi.org/10.1002/cpt.250 DOI: https://doi.org/10.1002/cpt.250
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Daiane Maria Cordeiro, Guilherme Antoniacomi Pereira, Rafael Nunes Borges
This work is licensed under a Creative Commons Attribution 4.0 International License.
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.
